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Multiple endocrine neoplasia type 2 is an autosomal-dominant hereditary cancer syndrome caused by missense
gain-of-function mutations of the rearranged during transfection proto-oncogene, which encodes the receptor
tyrosine kinase, on chromosome 10. It has a strong penetrance of medullary thyroid carcinomas and can be
associated with bilateral pheochromocytoma and primary hyperparathyroidism. Multiple endocrine neoplasia type
2 is divided into three varieties depending on its clinical features: multiple endocrine neoplasia type 2A, multiple
endocrine neoplasia type 2B, and familial medullary thyroid carcinoma. The specific rearranged during transfection
mutation may suggest a predilection toward a particular phenotype and clinical course of medullary thyroid
carcinoma, with strong genotype-phenotype correlations. Offering rearranged during transfection testing is the
best practice for the clinical management of patients at risk of developing multiple endocrine neoplasia type 2, and
multiple endocrine neoplasia type 2 has become a classic model for the integration of molecular medicine into
patient care. Recommendations on the timing of prophylactic thyroidectomy and extent of surgery are based on the
classification of rearranged during transfection mutations into risk levels according to genotype-phenotype
correlations. Earlier identification of patients with hereditary medullary thyroid carcinoma can change the
presentation from clinical tumor to preclinical disease, resulting in a high cure rate of affected patients and a much
better prognoses.
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INTRODUCTION
Multiple endocrine neoplasia type 2 (MEN2) is an
autosomal-dominant hereditary cancer syndrome caused
by missense mutations in the RET (REarranged during
Transfection) proto-oncogene, and these result in the gain-
of-function of the encoding receptor tyrosine kinase (1). The
estimated prevalence is 2.5 per 100,000 in the general
population. MEN2 shows a high penetrance for medullary
thyroid carcinoma (MTC), which is a rare calcitonin (Ct)-
secreting tumor derived from thyroid parafollicular or C-
cells of the thyroid; these cells are themselves derived from
the neural crest. Most patients with MTC have the sporadic
(i.e., non-familial) form of the tumor, while 25–30% present
with the hereditary form. MEN2 syndrome occurs in three
clinically distinct varieties with variable penetrance of MTC,
pheochromocytoma, and hyperparathyroidism. Early iden-
tification of patients with MTC changes the presentation
from a clinically evident tumor to a preclinical disease,
resulting in a higher cure rate of the affected patients with
much better prognoses (2). Each variant of MEN2 results
from a different mutation of the RET gene with good
genotype-phenotype correlations.
Phenotype: clinical description of MEN2
Three distinct clinical subtypes of MEN2 have been
characterized (Table 1). They differ with respect to incidence,
genetics, age-related penetrance, association with other
diseases, aggressiveness of MTC, and prognosis (3,4).
MEN2A syndrome (OMIM#171400) is characterized by the
presence of MTC, bilateral pheochromocytoma and/or
multiple tumors of the parathyroid glands (primary hyper-
parathyroidism) within a single patient or family. It is the
most common form of MEN2 syndrome, representing 55% of
cases (5). The frequency of MTC is .90% among patients
with MEN2A, while the frequencies of pheochromocytoma
and multiple parathyroid gland hyperplasia are 40–50% and
10–20%,respectively.MTC isgenerallythefirstmanifestation
of MEN2A and presents when patients are between 5 and 25
years of age. Rare variants of MEN2A exist, including
MEN2A with cutaneous lichen amyloidosis (this skin lesion
is located over the upper portion of the back) and MEN2A/
familial MTC (FMTC) with Hirschsprung’s disease (see
below).
MEN2B (OMIM#162300) is characterized by the associa-
tion between MTC, pheochromocytoma, the absence of
hyperparathyroidism, and visible physical stigmata such as
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69raised bumps on the lips and tongue (caused by cutaneous
neuromas), ganglioneuromas of the intestine, and asthenic
marfanoid body habitus with skeletal deformations and
joint laxity. Pheochromcytomas occur in 50% of individuals
with MEN2B, approximately half of these are multiple and
often bilateral; the development of mucosal neuromas on
the tongue and lips (bumpy lips) (resulting in a distinctive
facial appearance), together with a marfanoid body habitus,
allows for diagnosis at a first glance. Early diagnosis by
clinical means is difficult because of the gradual develop-
ment of the typical clinical appearance during childhood.
Diffuse ganglioneuromatosis of the gastrointestinal tract is
responsible for the megacolon, constipation and diarrhea
that often present. Because of their similar clinical presenta-
tions, the clinician should carefully differentiate the
diagnosis of Hirschsprung disease as a result of aganglio-
neuromatosis from MEN2B. Brauckhoff et al. reported that
86% of patients with MEN2B demonstrate an inability to cry
tears (6). It is the rarest form of MEN2 and accounts for 5–
10% of MEN2 cases. Patients with MEN2B typically present
with MTC during the first year of life and have a more
aggressive form of MTC with higher morbidity and
mortality rates than patients with MEN2A (4). Patients with
MEN2B often do not have a family history of the disease; in
more than 50% of cases the syndrome is due to a de novo
germline RET mutation.
FMTC (OMIM#155240) is characterized by a strong
predisposition to MTC in families with a very low incidence
of other endocrinopathies related to MEN2. It is clinically
diagnosed in families with four or more cases of MTC. It is
viewed as a phenotypic variant of MEN2A with decreased
penetrance of pheochromocytoma and primary hyperpar-
athyroidism. It has been diagnosed more frequently in
recent years and is reported to account for 35–60% of all
MEN2 cases (5,7-9). Regarding MTC in FMTC, penetrance is
lower and the clinical course is more benign than in MEN2A
and MEN2B, with a late onset or no clinically manifesting
disease and the prognosis is relatively good. Therefore, a
family history is often inadequate for establishing familial
disease.
Medullary thyroid carcinoma (MTC)
MTC originates from neural crest-derived Ct-producing
cells (C-cells). Hereditary MTC characteristically presents as
a multifocal process with C-cell hyperplasia (CCH) as the
precursor lesion to MTC. Only familial primary CCH is a
preneoplastic lesion. Secondary CCH, which has been
associated with chronic lymphocytic thyroiditis, hypergas-
trinemia, other follicular-cell-derived thyroid tumors and
even aging, has a much lower, if any, potential for
malignancy (10). The time frame for the progression from
CCH to microscopic carcinoma in MEN2 remains unclear,
but it may take years; the age of transformation from CCH
to MTC varies with different germline RET mutations. MTC
is diagnosed when nests of C-cells extend beyond the
basement membrane and infiltrate and destroy thyroid
follicles. MTC in MEN2 patients is multicentric and
concentrated in the upper third of the thyroid gland. The
peak incidence of sporadic MTC occurs in the fifth decade of
life, while hereditary MTC can be diagnosed earlier,
depending on the availability of genetic and biochemical
screenings. The mode of discovery of MTC has changed,
based on the use of specific strategies: serum Ct screening is
used for patients with thyroid nodules (11) and genetic
screening for RET proto-oncogene mutations is used for all
patients with MTC (9). The earlier identification of patients
with MTC has altered the presentation from symptomatic
tumors to a preclinical disease, resulting in a much better
prognosis with a higher cure rate. The average 5-year
survival for MTC is 83%, which is lower than that for
papillary and follicular thyroid cancers. The most important
predictor of survival is the tumor stage at diagnosis.
Metastasis may be found first in the central, lateral cervical
and mediastinal lymph nodes of the neck in 30% of patients
with MTC ,1 cm in diameter. Metastases outside the neck
and mediastinum may develop during the course of the
disease, predominantly in the lung, liver, and bone.
The primary secretory product of MTC is Ct, which serves
as a tumor marker for MTC. The normal concentration
of mature Ct is ,10 pg/ml and after stimulation it
is ,100 pg/ml. The Ct secretagogues are pentagastrin
(0.5 mg/kg body weight), which is no longer available in
the USA, and calcium (0.25 mg/kg body weight) (12). Basal
Ct levels are elevated in some patients with renal
insufficiency, autoimmune thyroid disorders or hypergas-
trinemia. This has to be taken into account when discussing
elevated Ct levels. Either basal or stimulated plasma Ct
levels using pentagastrin or calcium are elevated in virtually
all patients with MTC. Basal Ct concentrations usually
correlate with tumor mass and are almost always high in
patients with palpable tumors (13). Similarly, following
surgery to remove a tumor, elevated plasma Ct levels are
indicative of persistent or recurrent disease.
Pheochromocytoma
The clinical manifestation of pheochromocytoma asso-
ciated with MEN2 is similar to that seen in sporadic cases,
with signs and symptoms such as headache, palpitations,
nervousness, tachycardia, and hypertension. Measurement
of plasma and/or 24-h urinary excretion of catecholamine
metabolites (e.g., epinephrine, norepinephrine, metanephr-
ine and normetanephrine) should be performed. Once the
biochemical diagnosis is made, imaging studies, such as
abdominal magnetic resonance imaging and/or computed
tomography, in addition to metaiodobenzylguanidine scan-
ning and/or fluorodopamine positron emission tomography,
Table 1 - Clinical classification of MEN2 and FMTC, and occurrence of MTC, associated tumors and other diseases.
Subtype Percentage of total cases
Typical age of onset
(years) MTC (%) Pheo (%) HPT (%) Associated diseases
MEN2A 56 10 100 50 25 Cutaneous lichen amyloidosis, Hirschsprung disease
MEN2B 9 2 100 50 Ganglioneuromatosis, marfanoid habitus
FMTC 35 30 95 Rare
FMTC: familial medullary thyroid carcinoma. HPT: primary hyperparathyroidism. MEN2: multiple endocrine neoplasia type 2. MTC: medullary thyroid
carcinoma. Pheo: pheochromocytoma.
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70are appropriate. Pheochromocytoma in MEN2 is almost
always located in the adrenal and is almost always benign.
The possibility of bilateral disease must be carefully
evaluated. The presence of pheochromocytoma must be
ruled out prior to any surgical procedure because if it is
untreated it can be lethal. Endoscopic adrenal-sparing
surgery has become the method of choice. The penetrance
of pheochromocytoma among different MEN2 kindreds
depends on specific RET germline mutations (see below)
(14). Pheochromocytoma usually becomes evident approxi-
mately 10 years later than the manifestation of MTC.
Therefore, it is usually identified when screening patients
with MEN2, often before clinical symptoms present.
Biochemical screening for pheochromocytoma should be
performed annually in MEN2 patients depending on their
genotype (see below), beginning at 8 years of age for carriers
of RET mutations associated with MEN2B and codon 634
mutations and by the age of 20 years for carriers of other
codon mutations. Because of the high risk to the fetus and
the mother, women with a RET mutation associated with
MEN2 should be screened for pheochromocytoma before
pregnancy.
Primary Hyperparathyroidism
Primary hyperparathyroidism is often clinically occult
and does not differ from that seen in patients with mild
sporadic primary hyperparathyroidism. It has been
reported in 10–25% of patients with MEN2A, but is rarely
the first manifestation of this syndrome (15,16). Diagnosis is
established by detecting high concentrations of intact
parathyroid hormone in the presence of hypercalcemia,
usually after the third decade of life. Pathological findings
show chief cell hyperplasia involving multiple glands and
sometimes multiple adenomas. Annual measurement of the
serum calcium concentration and parathyroid hormone in
gene carriers is probably adequate for screening purposes,
and should begin by age 8 years for carriers of RET
mutations in exon 10 and 11 and by age 20 years for carriers
of other MEN2A RET mutations. The goal for MEN2
patients with primary hyperparathyroidism is to excise the
enlarged glands and to leave at least one normal parathyr-
oid gland intact. If the glands are all enlarged, a subtotal
parathyroidectomy or total parathyroidectomy with auto-
transplantation should be performed.
Genotype of MEN2: RET proto-oncogene structure,
function and abnormalities
The genes responsible for MEN2 were found to be
localized in centromeric chromosome 10 (10q11.2) by
genetic linkage analysis in 1987. Subsequently, point
mutations of the RET (REarranged during Transfection)
proto-oncogene were identified in MEN2A, MEN2B, and
FMTC in eight exons located near this region (Figure 1)
(17,18). Analysis of RET in families with MEN2A and FMTC
revealed that nearly all of these families have germline
mutations, and that only those family members with the
germline missense mutations have the disease. This dis-
covery prompted major advances in the understanding of
the molecular and genetic basis of MTC, and has signifi-
cantly changed the clinical management of families with
hereditary tumors. Missense mutations have been reported
in exons 5, 8, 10, 11, and 13–16 of RET (http://arup.uta-
h.edu/database/MEN2/MEN2_welcome.php) (Figure 1)
(5). Genetic testing detects about 98% of mutation carriers
and is considered to be standard care for all first-degree
relatives of patients with newly diagnosed MTC. It is also
recommended for all patients with MTC, regardless of other
features or family history, especially those with clinical
features that are indicative of MEN2 and those with primary
CCH. About 4–10% of patients with apparently sporadic
MTC have germline mutations in the RET proto-oncogene
and, consequently, present with the hereditary form (8).
The RET gene consists of 21 exons and encodes a receptor
tyrosine kinase that appears to transduce growth and
differentiation signals in several developing tissues, includ-
ing those derived from the neural crest. The transcript
length is 5659 base pairs and is translates to a 1114 amino
acid-residue protein. The RET protein consists of an
extracellular segment with a ligand-binding domain, a
cadherin (Ca
2+-dependent cell adhesion)-like domain, and
a cysteine-rich domain that is positioned near the cell
membrane. The RET protein has a single transmembrane
domain and an intracellular segment with two tyrosine
kinase subdomains, TK1 and TK2. It is activated by ligand-
induced dimerization (19). RET binds ligands of the glial-
derived neurotrophic factor (GDNF) family in conjunction
with a co-receptor, designated GDNF-family receptor a,t oa
complex that triggers autophosphorylation and intracellular
signaling. RET is produced in neuroendocrine cells, includ-
ing C-cells of the thyroid (the precursors of MTC) and
pheochromocytomas.
Hereditary MTC is caused by autosomal-dominant gain-
of-function mutations in the RET proto-oncogene. Mutation
of the extracellular cysteine in codon 634 in exon 11 causes
ligand-independent dimerization of receptor molecules,
enhanced phosphorylation of intracellular substrates and
cell transformation. Mutation of the intracellular tyrosine
kinase (codon 918) has no effect on receptor dimerization
but does cause constitutive activation of intracellular
signaling pathways and also results in cellular transforma-
tion. There is a significant age-related progression from
CCH to MTC that correlates with the transformative
capacity of the particular RET mutation (2). Mutations that
strongly activate the RET proto-oncogene are associated
with a more aggressive form of MTC that presents earlier,
and mutations that provide weaker RET activation result in
a less aggressive form of the disease that presents later. On
the basis of this finding, a risk-stratification strategy has
been developed (see below). MTC is generally the first
neoplastic manifestation seen in patients with MEN2A
because of its earlier age of onset and higher rate of
penetrance compared with pheochromocytoma or parathyr-
oid hyperplasia. This indicates that C-cells are more
susceptible to oncogenic RET activation than adrenal
medullary or parathyroid cells.
RET has also been implicated in congenital aganglionosis
(absence of enteric nerve cells) in the gastrointestinal tract
(Hirschsprung disease). The lack of neuroenteric plexi
impairs smooth muscle activity of the intestines (particu-
larly the colon), resulting in refractory constipation. Up to
50% of familial cases and up to 35% of simplex cases (i.e., a
single occurrence in a family) of Hirschsprung disease are
caused by germline loss-of-function mutations in the RET
proto-oncogene (20). There are some families and indivi-
duals harboring germline RET mutations in exon 10 that co-
segregate with MEN2A/FMTC and Hirschsprung disease.
Because of a seemingly similar clinical presentation,
clinicians should be careful to differentiate the diagnosis
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that result from ganglioneuromatosis associated with
MEN2B.
Genotype-phenotype correlations in MEN2
Clear associations have been documented between
specific RET mutations (genotype) and the age of onset
and aggressiveness of MTC and the presence or absence of
other endocrine neoplasms (phenotype), such as pheochro-
mocytoma or hyperparathyroidism (Table 2) (2,21,22). Some
overlap exists between RET mutations and the resulting
clinical subtype of MEN2. Approximately 98% of families
with MEN2A have a RET mutation in exon 10 or 11.
Mutations in the cysteine of codon 634 occur in about 87% of
families; 95% of families with FMTC have an identifiable
RET mutation. These mutations typically occur in one of the
five cysteine residues (codons 609, 611, 618, 620, and 634 in
exons 10 and 11) or in exons 5, 8, and 13–16, with an
important minority affecting codons 790, 791, 768, and 804;
95% of individuals with the MEN2B phenotype have a
single-point mutation in the tyrosine kinase domain of the
RET gene at codon 918 in exon 16, and this substitutes a
threonine for methionine (M918T) (Figure 2). A second
mutation at codon 883 in exon 15, A883F, has been
identified in several affected individuals without a M918T
mutation (4). In addition to these well-known and clinically
well-characterized mutations, more than 140 RET variants
are known. Half of these variants are pathogenic, and the
other half are benign or uncertain variants (http://arup.
utah.edu/database/MEN2/MEN2_welcome.php).
In newly detected germline RET sequence changes it is
mandatory to clarify if the ‘‘mutation’’ is causative of MEN2
and if it segregates with the MEN2 disease symptoms
within a family. The web-based Associated Regional and
University Pathologists (ARUP) online Scientific Resource
RET database (http://arup.utah.edu/database/MEN2/
MEN2_welcome.php) uses the following classification def-
inition: mutation, polymorphism, and variant of unknown
significance (VUS). Mutation is defined as causative for the
disease and segregates with the disease if the following
conditions are met: (1) if there are at least two affected
family members and at least one has MTC and one other
family member has one clinical feature of MEN2; (2) if one
patient has MTC and another has MEN2 clinical features; or
(3) if at least three unrelated individuals with MTC have the
same germline RET sequence variant. Polymorphisms are
harmless germline RET sequence changes that are not
causative of MEN2, and they include G691S, L769L, S836S,
S904S and intron 14 c.2608-24G.A. It is speculated that
some of the normal allelic variants may be modifying factors
in patients with pathologic RET mutations (23-25). VUS are
RET sequence changes in which there is not enough clinical
evidence to indicate a causative role, so further clinical
studies, in vitro experiments (e.g., kinase activity assay), and
prediction algorithms are necessary to clarify whether the
sequence change is a mutation or a polymorphism. One
Figure 1 - Germline mutations in the RET proto-oncogene associated with MEN2 and FMTC. Numbers indicate the mutated codons of
the RET gene.
Table 2 - Management of patients with different RET mutations (4).
Characteristic/management
Codons 321, 515, 533, 600, 603,
606, 635, 649, 666, 768, 776, 790,
791, 804, 819, 833, 844, 861, 891,
912
Codons 609, 611, 618, 620,
630, 631 Codon 634 Codons 918, 883
ATA risk level (2009)
a AB C D
MEN2 subtype FMTC FMTC/MEN2A MEN2A MEN2B
MTC aggressiveness Moderate High Higher Highest
MTC age of onset Adults 5 years Before the age of 5 years First year of life
Timing of prophylactic
thyroidectomy
When calcitonin rises/age 5 or 10
years
5 years Before the age of 5 years First months of life
Screening for Pheo Start at 20 years, periodically Start at 20 years, annually Start at 8 years, annually Start at 8 years, annually
Screening for HPT Start at 20 years, periodically Start at 20 years, periodically Start at 8 years, annually -
ATA: American Thyroid Association. FMTC: familial medullary thyroid carcinoma. HPT: primary hyperparathyroidism. MTC: medullary thyroid carcinoma.
Pheo: pheochromocytoma.
aRisk for aggressive MTC; level D is the highest risk (4).
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72example of this is the S649L and Y791F RET germline
sequence variants that have been described and verified as
mild mutations by some (26-28) and as non-pathogenic by
others (29). Using the Bayes classification to predict the
disease associations of uncertain gene variants into cate-
gories of benign and pathogenic, amino acid-substitution
penalties, structural disruption, sequence homology (e.g.,
ortholog conservation) or neural nets, the RET Y791N
sequence changes are classified as pathogenic (30). Further
clinical studies are necessary to classify VUS as deleterious
mutations before guiding therapy by the codon positions of
these RET mutations.
Clinical implications of genotype-phenotype
correlations
Patients with a codon 918 mutation and MEN2B are at
high risk of aggressive MTC occurring at a young age (31).
In contrast, patients with codon 791 mutations are at a
relatively low risk of aggressive disease and develop slow-
growing tumors as a late manifestation (27). According to
recent data, membrane proximity of the mutation seems to
be an important determinant of tumor development in
carriers of RET mutations in exon 10 (32,33). These
genotype-phenotype correlations between mutation, age of
onset, tumor aggressiveness, and onset of pheochromocy-
toma and parathyroid disease may be used to predict the
phenotype and make recommendations regarding the ages
at which to perform prophylactic thyroidectomy and begin
biochemical screening for pheochromocytoma and hyper-
parathyroidism (Table 2). This is particularly true in
presymptomatic RET mutation carriers because a prophy-
lactic thyroidectomy should be performed before the
development of MTC, or at least when the MTC is confined
within the thyroid and before the spread of disease beyond
the gland. The multicentric and bilateral nature of heredi-
tary MTC implicates a total thyroidectomy.
Recommendations for the timing of prophylactic thyr-
oidectomy and the extent of surgical resection are based on
a model that utilizes these genotype-phenotype correlations
to stratify mutations into risk levels (A–D) (Table 2) (4).
Patients with American Thyroid Association (ATA) A
mutations (exon 5, codon 321; exon 8, codons 531, 515 and
533; exon 10, codons 600, 603 and 606; exon 11, codons 649
and 666; exon 13, codons 768, 777, 790 and 791; exon 14,
codons 804, 819, 833 and 844; and exon 15, codons 866, 891
and 912), which mainly include phenotypic FMTC, are at
the lowest risk for the development and aggressiveness of
MTC; patients with ATA B mutations (exon 10, codons 609,
611, 618 and 620; and exon 11, codons 630, 631 and 633) are
at intermediate risk; patients with ATA C mutations, the
classical MEN2A mutation (exon 11, codon 634) are at a
higher risk than patients with ATA B mutations; and
patients with ATA D mutations have the typical MEN2B
mutation (exon 15, codon 883; and exon 16, codon 918) and
are at the highest risk of developing MTC with a high rate of
growth.
In the cases of these higher risk mutations, thyroidectomy
is recommended before 5 years of age for patients with ATA
C mutations and as early as possible, preferably within the
first year after birth, for patients with ATA D mutations (4).
For patients with ATA A mutations, there are various
recommendations regarding the appropriate age at which to
perform prophylactic surgery: some authors suggest thyr-
oidectomy at 5 years of age, some at 10 years, while others,
including the present authors (27), suggest that surgery may
be postponed until an abnormal C-cell stimulation test
result is obtained (i.e., an abnormal Ct response to
pentagastrin or calcium stimulation). However, further
studies, particularly regarding rare and/or newly diag-
nosed mutations (26), are necessary before general recom-
mendations can be made. In order to avoid complications
such as recurrent laryngeal nerve injuries or hypopathyr-
oidism, the operation should be performed by surgeons
who perform a high volume of this type of procedure.
The association between disease phenotype and RET
genotype may also have important implications for the
management of clinical presentations other than MTC in
MEN2 patients and their families. If the genotype could be
fully correlated with certain phenotypic features, then a
clinician could use a patient’s genotype to decide whether
intense screening for pheochromocytoma or HPT is neces-
saryinthosepatientswithmutationsassociatedwithahigher
risk of disease (Table 2). Pheochromocytoma is associated
Figure 2 - Distribution of RET mutations, as determined by the Molecular Genetics Laboratory, Heidelberg, Germany, 2000–2011.
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73with exon 634 and 918 mutations in approximately 50% of
patients, with exon 10 mutations (codons 609, 611, 618 and
620) in up to 17% of patients (33), and rarely with mutations
in exons 13–15 (codons 791 and 804; Tables 1 and 2) (14,34).
Hyperparathyroidism in MEN2A is most commonly asso-
ciatedwithcodon634 mutationsandC634Rinparticular(35).
All cases of MEN2A with Hirschsprung disease are
associated with mutations in exon 10 (codons 609, 611,
618, and 620); in an unselected, multinational study on
carriers of exon 10 mutations, 7.5% of informative carriers
were found to also have a Hirschsprung disease phenotype
(33). MEN2A with cutaneous lichen amyloidosis is asso-
ciated with mutations in codon 634 (36).
Perspectives: screening and genetic counseling
MEN2 is a monogenic disorder and, according to its
autosomal-dominant pattern of inheritance, each affected
individual has a 50% probability of transmitting the
defective gene to progeny, independent of sex. Predictive
DNA tests are available; therefore, it is worthwhile to screen
both first- and second-grade family members. In clinically
demonstrable MTC, the specific RET mutation gives
information on the risk of developing pheochromocytoma
and HPT, the aggressiveness of MTC and clinical prognosis.
By screening family members, genetic testing allows for
early treatment and, thereby, offers the chance of prophy-
lactic thyroidectomy and curing the patient of MTC.
From a medical point of view, MEN2 offers a unique
model of how to use genetic information to cure a patient
with a hereditary cancer syndrome. From the point of view
of the patient, there is a loss of privacy and autonomy and a
feeling of stigmatization and discrimination. There appears
to be a threshold for patients to inform their relatives about
this hereditary disease. The confidentiality of genetic testing
must be absolute, with no exception; therefore, the duty to
inform relatives who may be at risk depends on the moral
obligation of the patient. However, many guidelines do
allow for the disclosure of results to at-risk individuals
without the patient’s consent when the information that will
be disclosed will prevent serious harm (4). Our social
attitude to rare hereditary diseases has to be reconsidered.
We need precise laws to prevent discrimination concerning
full insurance coverage and employment. Patient interest
groups may be able to providing information, support
during times of emotional distress and stand up for
common political and social aspects.
Early identification of patients with hereditary MTC using
DNA screening changes the presentation from a clinical
tumor (index case) to a preclinical disease (screening case),
resulting in a high cure rate of the affected patients by using
presymptomatic treatments, improved life expectancy and
quality of life.
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